Document is current
Any future updates will be listed below
-
Authors
Camon, Ana M.
Alonso, Rodrigo
Muñoz, Francisco J.
Cardozo, Celia
Bernal-Maurandi, Javier
Albiach, Laia
Agüero, Daiana
Marcos, M. Angeles
Ambrosioni, Juan
Bodro, Marta
Chumbita, Mariana
De la Mora, Lorena
Garcia-Pouton, Nicole
Dueñas, Gerard
Hernandez-Meneses, Marta
Inciarte, Alexy
Cuesta, Genoveva
Meira, Fernanda
Morata, Laura
Puerta-Alcalde, Pedro
Rico, Verónica
Herrera, Sabina
Tuset, Montse
Castro, Pedro
Prieto-González, Sergio
Almuedo, Alex
Muñoz, José
Mensa, Josep
Sanjuan, Gemma
Nicolas, J. M.
Del Rio, Ana
Vila, Jordi
García, Felipe
Martínez, José Antonio
Garcia-Vidal, Carolina
Soriano, Alex
,
,
Blanco, J. L.
Mallolas, J.
Martínez, E.
Martínez, M.
Miró, J. M.
Moreno, A.
Solá, M.
Ugarte, A.
Gonzalez-Cordón, Ana
Laguno, Montse
Leal, Lorna
Rojas, John
Torres, Berta
,
,
Fernandez, S.
Tellez, A.
Fuentes, F.
Ayala, M.
Sancho, E.
,
Campubri, D.
de Alba, M. T.
Fernandez, M.
Ferrer, E.
Grau, B.
Marti, H.
Muelas, M.
Pinazo, M. J.
Rodriguez, N.
Roldan, M.
Subira, C.
Vera, I.
Williams, N.
Almuedo-Riera, A.
,
,
Aldea, A.
Camafort, M.
Calvo, J.
Capdevila, A.
Cardellach, F.
Carbonell, I.
Coloma, E.
Foncillas, A.
Estruch, R.
Feliu, M.
Fernández-Solá, J.
Fuertes, I.
Gabara, C.
Grafia, I.
Ladino, A.
López-Alfaro, R.
López-Soto, A.
Macaya, I.
Masanés, F.
Matas, A.
Navarro, M.
Hernández, J. Marco-
Miguel, L.
Milisenda, J. C.
Moreno, P.
Naval, J.
Nicolás, D.
Oberoi, H.
Padrosa, J.
Pellicé, M.
Ribot, J.
Rodríguez-Núnez, O.
Sacanella, E.
Seguí, F.
Sierra, C.
Tomé, A.
Torres, M.
Ventosa, H.
Zamora-Martínez, C.
,
,
Almela, M.
Alvarez, M.
Bosch, J.
Costa, J.
Cuesta, G.
Fidalgo, B.
Gonzàlez, J.
Marco, F.
Narvaez, S.
Pitart, C.
Rubio, E.
Vergara, A.
Valls, M. E.
Zboromyrska, Y.
,
,
López, E.
,
- License Information
-
More Information
Article History
Received: 8 September 2021
Accepted: 8 March 2022
First Online: 28 March 2022
Competing interests
: CGV has received honoraria for talks on behalf of Gilead Science, MSD, Novartis, Pfizer, Jannsen, and Lilly, as well as a grant from Gilead Science and MSD. PPA has received honoraria for talks on behalf of Gilead Science and MSD. JM has received honoraria for talks on behalf of Merck Sharp and Dohme, Pfizer, Novartis, and Angellini. AS has received honoraria for talks on behalf of Merck Sharp and Dohme, Pfizer, Novartis, Gilead, Menarini, and Angellini, as well as grant support from Pfizer and Gilead. MT has received grants from Janssen, Gilead, ViiV and Merck Sharp and Dohme. LM has received honoraria for talks on behalf of Merck Sharp and Dohme, Pfizer and Angellini. PC has received honoraria for talks on behalf of Merck Sharp and Dohme, has participated in Advisory Boards for Gilead and Alexion, and has received grant support from Pfizer and Gilead. Other authors do not declare conflict of interest.
